The use of the antibody navenibart, being developed by Astria Therapeutics to prevent swelling episodes in …
Articles by Margarida Maia, PhD
Keeping symptoms of hereditary angioedema (HAE) under control is the most important factor contributing to a better quality of…
More than half of individuals admitted to an emergency department, or ED, for drug-induced nonallergic angioedema — with nearly…
Sebetralstat, an oral small molecule being developed by Kalvista Pharmaceuticals, provided adults and adolescents with hereditary angioedema…
An assay that measures C1 inhibitor (C1-INH) activity on a dried blood spot after a blood sample is blotted onto…
Pharvaris plans a trial of deucrictibant to treat acquired angioedema this year, following promising data showing the…
Garadacimab appears to be safe for long-term use as prophylaxis, or preventive treatment, reducing the frequency of swelling attacks…
Many people with hereditary angioedema (HAE) delay on-demand treatment for their attacks because they think the swelling isn’t severe…
People with hereditary angioedema (HAE) who have normal C1-inhibitor (C1-INH)Â levels and activity appear to have more active disease and…
Transitioning from other prophylactic, or preventive, treatments, to Orladeyo (berotralstat) or Takhzyro (lanadelumab) can take some time and…